These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 33994538)

  • 21. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRNA therapeutics in cancer immunotherapy.
    Beck JD; Reidenbach D; Salomon N; Sahin U; Türeci Ö; Vormehr M; Kranz LM
    Mol Cancer; 2021 Apr; 20(1):69. PubMed ID: 33858437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside.
    Roy S; Sethi TK; Taylor D; Kim YJ; Johnson DB
    J Leukoc Biol; 2020 Oct; 108(4):1455-1489. PubMed ID: 32557857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Vaccines - SMi's Fourth Annual Conference (September 16-17, 2015 - London, UK).
    Searle B
    Drugs Today (Barc); 2015 Sep; 51(9):569-73. PubMed ID: 26488036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent developments in neoantigen-based cancer vaccines.
    Hodge K; Supabphol S; Kumar P; Poomipak W; Pisitkun T
    Asian Pac J Allergy Immunol; 2020 Jun; 38(2):91-101. PubMed ID: 32563235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mRNA Cancer Vaccines.
    Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
    Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
    Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
    Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photosynthetic Bacteria-Hitchhiking 2D iMXene-mRNA Vaccine to Enable Photo-Immunogene Cancer Therapy.
    Zhang S; Yu J; Liu Y; Xiong B; Fang Y; Zhu Y; Li S; Sun L; Zhou B; Sun Y; Wang L; Yue W; Yin H; Xu H
    Adv Sci (Weinh); 2024 Jul; 11(28):e2307225. PubMed ID: 38742454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
    Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
    Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity.
    Mai Y; Guo J; Zhao Y; Ma S; Hou Y; Yang J
    Cell Immunol; 2020 Aug; 354():104143. PubMed ID: 32563850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA-Based Vaccines in Cancer Immunotherapy.
    McNamara MA; Nair SK; Holl EK
    J Immunol Res; 2015; 2015():794528. PubMed ID: 26665011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
    Deng Z; Tian Y; Song J; An G; Yang P
    Front Immunol; 2022; 13():887125. PubMed ID: 35720301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer mRNA vaccines: clinical advances and future opportunities.
    Sayour EJ; Boczkowski D; Mitchell DA; Nair SK
    Nat Rev Clin Oncol; 2024 Jul; 21(7):489-500. PubMed ID: 38760500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
    Martin SD; Coukos G; Holt RA; Nelson BH
    Ann Oncol; 2015 Dec; 26(12):2367-74. PubMed ID: 26371284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 39. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
    Kim CG; Sang YB; Lee JH; Chon HJ
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalized cancer vaccines: Targeting the cancer mutanome.
    Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
    Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.